Interestingly, dasatinib has been shown to reduce the expression of ALDH1A1, leading to potentiation of gemcitabine in a gemcitabine-resistant pancreatic cancer cell line [520]. The gene discussed is ALDH1A1; the disease is pancreatic neoplasm.